IL6 and colitis: In vivo, DPG decreases the severity of DSS-induced colitis as well as intestinal inflammation reduction mediated by a downregulation of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, as well as HMGB1 receptors, RAGE, and TLR4 [34].